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Abstract
Background: It has been reported that lack of insight is significantly associated with cognitive
disturbance in schizophrenia. This study examines the longitudinal relationships between insight
dimensions and cognitive performance in psychosis.
Methods: Participants were 75 consecutively admitted inpatients with schizophrenia, affective
disorder with psychotic symptoms or schizoaffective disorder. Assessments were conducted at
two time points during the study: at the time of hospital discharge after an acute psychotic episode
and at a follow-up time that occurred more than 6 months after discharge. A multidimensional
approach of insight was chosen and three instruments for its assessment were used: the Scale to
Assess Unawareness of Mental Disorder (SUMD), three items concerning insight on the
Assessment and Documentation in Psychopathology (AMDP) system and the Insight and
Treatment Attitudes Questionnaire. The neuropsychological battery included a wide range of tests
that assessed global cognitive function, attention, memory, and executive functions.
Results: After conducting adequate statistical correction to avoid Type I bias, insight dimensions
and cognitive performance were not found to be significantly associated at cross-sectional and
longitudinal assessments. In addition, baseline cognitive performance did not explain changes in
insight dimensions at follow-up. Similar results were found in the subset of patients with
schizophrenia (n = 37). The possibility of a Type II error might have increased due to sample
attrition at follow-up.
Conclusion: These results suggest that lack of insight dimensions and cognitive functioning may
be unrelated phenomena in psychosis.
Background
Psychosis is expressed through a wide range of psycho-
pathological phenomena and different outcomes. The
neurobiological underpinnings of psychosis remain
unknown despite extensive research in the last century.
The clinical heterogeneity within psychosis has led to a
debate concerning what the 'core' manifestations of psy-
chosis are, which is still progressing [1]. However, it is
widely acknowledged that lack of insight is the most prev-
alent symptom in psychosis [2] and it has a notable influ-
ence on cooperation with treatment and clinical outcome
in psychotic patients [3].
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Insight involves different underlying phenomena and
now includes multidimensionality as an attribute [4].
Two multidimensional models are widely accepted.
David [5] hypothetized that insight comprises three
dimensions: recognition that one has a mental illness, the
ability to relabel unusual mental events as pathological,
and adherence with treatment. These insight dimensions
are overlapping, dimensional and dynamic phenomena,
which allow for particular variations along the course of
the illness. This model holds face validity and has also
been used by our group and others [6]. The other multidi-
mensional model, proposed by Amador et al [4], distin-
guishes between the two main components of insight:
unawareness of illness and incorrect attribution of deficit
or consequence of illness. Provided that insight is a
dynamic symptom domain and may change along the
course of the illness, Amador et al developed an assess-
ment scale that allows for current and retrospective assess-
ments of these two main components of insight.
Explanations of the causes of lack of insight are purely
hypothetical and pending clarification. Psychological
processes [7,8], neurocognitive mechanisms [4] and psy-
chopathological explanations have been proposed as
explanations [9]. Two methods for exploring the hypo-
thetical neurocognitive dysfunction associated with lack
of insight have been used: neuroimaging procedures and
neuropsychological assessment. Inconsistent findings
have been reported by nine neuroimaging studies that
focused on insight. Four out of the nine studies reported
significant associations between lack of insight and either
ventricular enlargement [10], smaller brain and intracra-
neal volumes [11], frontal lobe atrophy [12], bilateral vol-
ume reductions in middle frontal gyrus, gyrus rectus, and
left anterior cingulate gyrus [13] or paralimbic structures
[14]. However, these results should be taken as inconclu-
sive due to severe limitations in the studies that reported
positive findings. These limitations included the absence
of specific instruments for the assessment of insight [10]
and the inclusion of small samples [11,12]. In addition,
many of these studies were performed with patients with
chronic schizophrenia, making it difficult to disentangle
the effects of illness chronicity and exposure to antipsy-
chotic drugs. To overcome this limitation, two studies
examined the relationship between insight in first-epi-
sode psychotic patients and specific brain regions, such as
the cingulated gyrus and dorsolateral prefrontal cortex,
respectively [15,16]. In addition, significant correlations
were not found between cerebral ventricular enlargement
and insight in a large set of individuals with recent onset
psychosis [17], as well as in another recently published
study from the same group [18].
Conflicting findings have emerged concerning the rela-
tionship between insight and neuropsychological per-
formance in psychosis. Although several methodological
limitations have hampered the results, 37 studies (33
cross-sectional and four longitudinal studies) have been
carried out. Out of the 33 cross-sectional studies, 22
showed significant relationships with executive measures
[7,8,18-30] or other neuropsychological tests [31-36]. In
addition, significant relationships between insight and
neuropsychological [9,37-44] or intellectual performance
[11,45] were not found in one-third of the 33 cross-sec-
tional studies. In regards to longitudinal studies, three out
of the four studies did not show significant associations
between insight and cognitive performance [17,46,47].
However, executive and memory domains were associated
with lack of insight in one study [48] and positive atti-
tudes towards medication were associated with better per-
formance on tests of verbal working memory in a forensic
sample of patients with schizophrenia [49].
The variability in these findings may be accounted for by
the different instruments used to assess insight and cogni-
tive functioning, design limitations (i.e., cross-sectional
design), or a lack of statistical power in the studies. The
present study was conducted to examine if cognitive dys-
function can predict the degree of insight into illness in
patients suffering from psychosis. A dimensional
approach and a longitudinal design were used. Specifi-
cally, our study was developed from the hypothesis that
lack of insight is not determined by a neuropsychological
disturbance. The objectives were to ascertain: whether
cross-sectional neuropsychological disturbance is associ-
ated with insight dimensions at the time of hospital dis-
charge after a psychotic episode and after a long period of
stabilization and if baseline neuropsychological perform-
ance predicts disturbances on insight dimensions at fol-
low-up.
Method
The study design was longitudinal and involved assess-
ments at two different time points. The assessments meas-
ured multidimensional aspects of insight,
psychopathological status and neuropsychological per-
formance in a group of patients suffering from psychosis.
This report presents a brief description of the study's
methodology, as a description of the sample and psycho-
pathological and insight assessment procedures have
been reported elsewhere [50].
Patients
The study group consisted of 75 patients who were con-
secutively admitted to a psychiatric unit due to an acute
psychotic episode. The patients were assessed after the
remission of the acute episode and six months to two
years after discharge from the hospital. The second assess-
ment occurred at a time when the patient was experienc-
ing a phase of clinical stabilization (n = 56). Patients metBMC Psychiatry 2006, 6:26 http://www.biomedcentral.com/1471-244X/6/26
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DSM-IV [51] criteria for schizophrenia (n = 37), affective
disorder with psychotic symptoms (n = 27) and schizoaf-
fective disorder (n = 11). The Comprehensive Assessment
Schedule History (CASH) [52] was used as a semistruc-
tured interview derive each patient's diagnosis and to
assess psychopathology at baseline and follow-up. Inter-
rater reliabilities for the positive and negative symptom
scales have been reported as good to excellent [53]. The
psychopathological, depressive and manic dimensions
from Liddle's three-syndrome model [54] were computed.
Clinicians completed the Clinical Global Impression scale
(CGI) [55]. The CGI is a 7-point scale ranging from 1(very
much improved) to 7(very much worse). This scale was com-
pleted during the baseline and follow-up assessments
periods of this study.
There were 19 patients that dropped out of the study and
were not available for follow-up assessment. Our research
program and its included protocols were approved by the
Ethic Committee of our Hospital. Participants gave their
informed consent to collaborate in the assessment proce-
dures. Patients with a history of organic central nervous
system disorder, drug or alcohol abuse in the past year or
mental retardation were excluded.
Procedure and assessment measures
The assessment of insight utilized three instruments: (a)
the Scale to assess Unawareness of Mental Disorder
(SUMD) [56], (b) the Insight and Treatment Attitudes
Questionnaire (ITAQ) [57], and (c) three insight items
from the Manual for the Assessment and Documentation
in Psychopathology (AMDP) [58]. The AMDP items were
lack of feeling ill, lack of insight and uncooperativeness.
Insight assessment was conducted in two sessions: the
AMDP insight items and the SUMD were administered
during the first session and the ITAQ was administered
during the second session. The SUMD assessments were
conducted by one of the researchers (MJC). The AMDP
items were scored by MJC & VPM. The third researcher
(AZ) scored the ITAQ. The authors participated in a pilot
study in order to reach a consensus on ratings that were
obtained using the three insight instruments. The proce-
dure for this pilot study involved the authors completing
independent ratings of interviews that were conducted
with fifteen patients who were consecutively admitted to
the hospital with a psychotic episode. This procedure was
followed by a discussion about each patient in order to
reach consensus ratings. High inter-rater reliability
between the two raters for AMDP-insight items has been
previously reported [9]. Each evaluator was blind to the
measures of the other researchers. A description of the
three instruments has been reported elsewhere [50].
Neuropsychological assessment
A neuropsychological battery was selected to provide a
wide assessment of cognitive functions. These instru-
ments measured cognitive functions that are commonly
disturbed in schizophrenia, such as attention, memory
and executive functions. The Information test of the WAIS
was used to assess global [59]. Immediate and delayed
verbal memory, and verbal fluency were assessed by
means of subtests of a Spanish-adapted neuropsychologi-
cal battery [60]. The immediate and delayed Verbal Mem-
ory tasks of our battery were very similar to the Logical
Memory tests of the Wechsler Memory Scale. The Verbal
Fluency test consisted of the recording of the number of
animals in 1 minute. Attention and executive function
were assessed with two tests: the form B of the Trail Mak-
ing Test [61] and the Stroop Color Word Test [62]. Finally,
the Wisconsin Card Sorting Test (WCST) [63] was also
used as a measure of executive function. Baseline insight
and cognitive assessments took place after remission of
the acute episode, during the days just before discharge
(mean admission duration 3.67 ± 3.1 weeks).
Statistical analysis
Initially, inspection of variables was carried out and those
variables non-normally distributed were transformed.
Pearson correlation analyses between cognitive and
insight measures were carried out at baseline and follow-
up assessments. Bonferroni inequality correction was cho-
sen to account for a high number of statistical tests [64].
The potential confounding effect of length of illness and
illness severity over cognition and insight was tested by
means of 'partial correlation' analyses.
As a complementary analytical methodology used to
avoid conducting a large number of statistical procedures
and to analyze insight dimensions, the data was summa-
rized by means of two separated 'principal component
factor analyses' of baseline insight and of neuropsycho-
logical variables. Oblique rotation was chosen to avoid
symptom overlapping on factors and to extract meaning-
ful factors of cognitive variables. In order to match these
baseline factors with the same factors at the follow-up
assessment, the same variables were used in two 'factor
analyses' that were carried out at follow-up. The number
of resulting factors was fixed 'a priori' to the same number
of factors of respective baseline assessments.
Longitudinal relationships between psychopathology and
insight were analyzed through multiple regression analy-
ses. Specifically, we assessed whether baseline cognitive
dimensions predicted change in insight at follow-up. Pre-
diction estimates were calculated through a stepwise mul-
tiple regression. The variables were entered into the model
at a probability of F = 0.05, and were removed at F = 0.1.BMC Psychiatry 2006, 6:26 http://www.biomedcentral.com/1471-244X/6/26
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Statistical analyses were performed using Statistical Pack-
age for the Social Sciences (SPSS Inc, Chicago).
Results
Table 1 displays the descriptive results of the demo-
graphic, insight and neuropsychological variables. Attri-
tion bias (25%) during the study was examined through
comparisons of basal insight and basal cognitive dimen-
sions between refusing patients and those patients who
remained in the study. Patients who refused showed lower
educational background than patients who remained in
the study (t = 2.44, p ≤ 0.01). No significant statistical dif-
ferences between these two groups of patients on insight
or neuropsychological measures were found. A trend
towards significant differences was found between these
two groups on the lack of feeling ill on the AMDP, how-
ever this result did not reach statistical significance after a
correction for the number of tests that were performed (t
= -.2.11, df = 73, p ≤ 0.038).
Differences between baseline and follow-up measures,
after applying Bonferroni inequality correction to account
for a high number of statistical procedures, are shown in
Table 2. Neuropsychological performance was relatively
stable across assessments, with the exception of improve-
ment on Information (WAIS), the Interference task of the
Stroop test and delayed verbal memory. Insight measures
only showed significant improvement on the ITAQ score
Table 1: Baseline sociodemographic, insight and neuropsychological variables comparison between patients remaining in the study and 
those who refused to participate in follow-up assessment.
Remaining patients (n = 56) Refusers (n = 19) t-pair test or chi-square P
Age 33,71 ± 9,00 35,00 ± 11,40 ,50 ,61
Education (years) 10,73 ± 3,24 9,21 ± 1,96 -2,44 ,01
N of episodes 5,16 ± 4,74 6,00 ± 7,08 ,57 ,56
Age at onset 24,53 ± 6,80 24,73 ± 8,51 ,10 ,91
Gender: males (%) 35 (62,5) 24 (64.9%) 1.12 .57
Civil: single (%) 41 (73,2) 30 (81.1%) 3.15 .20
PSYCHOPATHOLOGICAL DIMENSIONS
Psychotic 1 ± 1,18 1.37 ± 1.33 -1.13 .26
Negative 1,51 ± 1,15 1.58 ± 1.08 -.22 .82
Disorganization ,72 ± ,88 .70 ± .82 ,08 .93
Depression ,50 ± ,73 .63 ± .83 -.65 .51
Mania ,23 ± ,50 .26 ± .45 -.24 .81
INSIGHT MEASURES#
ITAQ (total score) 12,26 ± 7,58 10,63 ± 7,22 -,82 ,41
SUMD
Lack of Awareness, total score
Current illness 2,66 ± 1,36 3,02 ± 1,30 ,95 ,34
Past illness 2,63 ± 1,22 2,79 ± 1,27 ,49 ,62
Mistaken Attribution, total score
Current illness 2,65 ± 1,33 3,25 ± 1,29 1,53 ,13
Past illness 2,53 ± 1,26 3,13 ± 1,10 1,76 ,08
AMDP
Lack of feeling of illness 1,42 ± 1,12 2,05 ± 1,07 2,11 ,03
Lack of Insigt 1,64 ± 1,15 2,05 ± 1,07 1,36 ,17
Refusal of treatment ,82 ± ,99 ,78 ± 1,08 -,12 ,90
NEUROPSYCHOLOGICAL TESTS
Edinburgh test 12.47 ± .4.91 12.89 ± 8.16 -.44 .66
Information (WAIS) 11.04 ± .2.46 10.68 ± 2.19 .73 .46
Word Fluency 15.97 ± .4.64 15.63 ± 5.64 .37 .71
Stroop PC 30.53 ± .7.97 29.84 ± 9.30 .43 .66
Stroop Interference 42.41 ± .7.72 42.68 ± 10.14 -.18 .86
WISCONSIN CARD SORTING TEST
Perseverative responses 30.81 ± .22.50 27.05 ± 17.04 .84 .40
Number of categories 3.88 ± .1.97 3.87 ± 2.01 -.04 .97
Trail Making test B (seconds) 181.96 ± 117.30 216.89 ± 149.66 -1.26 .21
Inmediate Verbal Memory 11.74 ± 3.81 10.92 ± 4.64 1.09 .27
Delayed VerbalMemory 11.72 ± 4.19 10.84 ± 4.39 1.06 .29
# Higher scores on ITAQ. Lower scores in awareness into symptoms and attribution scales of SUMD scale and AMDP items reflected better 
insight.BMC Psychiatry 2006, 6:26 http://www.biomedcentral.com/1471-244X/6/26
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and a trend toward significant improvement on the
AMDP 'Lack of feeling of illness' score.
Pearson correlation coefficients between cognitive and
insight measures, both at baseline and at follow-up assess-
ments, were carried out. As demonstrated in Table 3, no
significant correlation coefficients were found after apply-
ing Bonferroni correction. The AMDP 'Refusal of treat-
ment' score at follow-up showed trends towards a
significant association with both the Interference task of
Stroop test and the WCST 'number of categories' score.
The factor analysis of the fourteen insight measures
resulted in two insight dimensions, as described else-
where [50]. The first factor was the 'general awareness'
dimension with high loading on all SUMD items. The sec-
ond factor reflected 'attitudes to treatment', with high
weightings on the ITAQ total score and the AMDP refusal
of treatment item and moderate loading on the AMDP
lack of feeling ill and the AMDP lack of insight items.
A principal components factor analysis of the neuropsy-
chological scores yielded five factors, which are named in
order of extraction as follows: (a) 'general cognitive', (b)
'perseverative', (c) 'non-perseverative errors', (d) 'ineffi-
cient sorting', and (e) 'attentional-executive' factors. The
following is a description of the results for the component
symptoms and factor loading of symptoms on each factor.
The 'general cognition' factor included the WAIS informa-
tion test (.73), memory tests (immediate .90 and delayed
.88), verbal fluency (.55), the Stroop color-word test (.56)
and the Trail Making B test (-.54). The second factor,
namely the 'perseverative' dimension, was comprised of
the number of perseverative errors (.91) and the number
of categories of the WCST (-.92). The third factor was the
'non-perseverative errors' dimension, which included
non-perseverative errors (.70), unique responses (.77)
and the number of perseverative errors (.53) on the
WCST. The 'inefficient sorting' factor was made up of two
WCST parameters: failure to maintain the set (-.93) and
the number of corrects minus ten (-.86). The fifth factor
was a mixed attentional and executive factor with high
loading on the Stroop color-word test (.88) and the Trail
Making B test (-.49). A five-factor solution was forcibly
extracted at follow-up and an analogy between baseline
and follow-up structures was established on the basis of
composition and loading of items on factors. The order of
extraction of factors varied from baseline to follow-up
assessments.
The Bonferroni inequality correction was applied between
insight and neuropsychological dimensions and no sig-
Table 2: Differences between baseline and follow-up assessments on insight and neuropsychological variables.
BASELINE ASSESSMENT FOLLOW-UP ASSESSMENT STATISTICAL DIFFERENCES
Mean SD Mean SD t-pair test p
Insight Measures# ITAQ (total 
score)
12.26 7.58 16.21 7.61 -4.54 .001
SUMD
Lack of Awareness, total score
Current illness 2,66 1.36 2.45 1.15 1.69 .10
Past illness 2.63 1.22 2.39 1.20 1.02 .31
Mistaken Attribution, total score 
Current illness
2.65 1.33 2.97 1.12 -.79 .43
Past illness 2.53 1.26 2.83 1.28 -.26 .79
AMDP
Lack of feeling of illness 1.42 1.12 1.01 1.14 3.12 .003
Lack of Insigt 1.64 1.15 1.30 1.08 2.30 .02
Refusal of treatment .82 .99 .41 .83 2.46 .01
Neuropsychological Tests
Information (WAIS) 11.04 2.46 11.87 2.54 -3.82 .001
Word Fluency 15.97 4.64 17.51 5.71 -2.06 .04
Stroop Interference 42.41 7.72 46.39 6.09 -4.12 .001
Perseverative Responses (WCST) 30.81 22.50 26.53 22.51 2.29 .02
Number of Categories (WCST) 3.88 1.97 4.06 2.03 -.72 .47
Trailb Making Test B (Seconds) 186.96 117.30 177.23 169.32 -.41 .68
Inmediate Verbal Memory 11.74 3.81 13.30 4.06 -2.69 .01
Delayed Verbal Memory 11.72 4.19 14.13 4.44 -3.94 .001
*Critical p value after Bonferroni correction (1 × 23) p ≤ 0.0021 (in bold)
# Higher scores on ITAQ. Lower scores in awareness into symptoms and attribution scales of SUMD scale and AMDP items reflected better insight.B
M
C
 
P
s
y
c
h
i
a
t
r
y
 
2
0
0
6
,
 
6
:
2
6
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
4
X
/
6
/
2
6
P
a
g
e
 
6
 
o
f
 
1
0
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 3: Pearson correlation coefficients between insight measures and neuropsychological test results at baseline (r0) and at follow-up assessments (r1)ab.
NEUROPSYCHOLOGICAL TESTS
78 9 1 0 1 1 1 2 1 3 1 4
r0 r1 r0 r1 r0 r1 r0 r1 r0 r1 r0 r1 r0 r1 r0 r1
ITAQ 1 .03(56) .02(56) .04(56) .12(56) .04(56) -.01(56) .01(56) -.03(56) -.04(56) -.06(56) .06(56) .03(56) .07(56) .16(56) .10(56) .23(56)
SUMD 
scorings
2 .10(47) -.19(41) .05(47) -.13(41) .07(47) -.11(41) -.10(47) .06(41) -.01(47) -.01(41) .08(47) .21(41) -.04(47) -.15(41) -.05(47) -.10(41)
3 .14(42) .03(37) -.11(42) .05(37) .08(42) -.11(37) .05(42) .12(37) -.09(42) -.13(37) -.05(42) .17(37) .03(42) .05(42) .01(42) -.01(37)
AMDP 
scorings
4 .01(56) .06(55) .05(56) .10(55) -.12(56) .12(55) -.07(56) .03(55) .05(56) -.10(55) -.07(56) -.06(55) -.13(56) .01(55) -.03(56) -.04(55)
5 .12(56) -13(55) -.01(56) -.10(55) .10(56) -.06(55) .03(56) 14(55) -.07(56) -.10(55) -.15(56) .12(55) -.03(56) -.14(55) -.06(56) -.13(55)
6 .04(56) .02(55) -.11(56) -.08(55) -.02(56) .25(55)* -.03(56) -.09(55) .07(56) -30(55)** -.16(56) -.05(55) -.08(56) -.05(55) -.06(56) .03(55)
1. ITAQ; 2. Awareness of illness (current illness); 3. SUMD Mistaken attribution (current illness); 4. AMDP. Lack of feeling of illness; 5. AMDP. Lack of Insight; 6. AMDP Refusal of treatment; 7. 
Information (WAIS); 8. Word Fluency; 9. Stroop Interference; 10. WCST. Persev. Responses; 11. WCST Number of Categories; 12. Trailb Making B; 13. Inmediate Verbal Memory; 14. Delayed 
Verbal Memory.
a = In brackets, it is shown the number of patients in each correlation
b = Critical p value after Bonferroni correction (p ≤ .05) for two different correlation sets (6 × 8) was r = .48, p ≤ .001 (95% confidence interval for significant associations for n = 56 ranged from 
r = .24 to r = .66).
*: r = .25 p ≤ .05; ** r = .35 p ≤ .01BMC Psychiatry 2006, 6:26 http://www.biomedcentral.com/1471-244X/6/26
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nificant cross-sectional associations were found at base-
line or follow-up (Table 4). The 'non-perseverative errors'
factor of cognitive function at baseline showed a trend
towards a significant correlation with the 'general aware-
ness' dimension of insight (r = -.27). To account for differ-
ences in length of illness among patients, 'partial
correlation' coefficient analyses between insight and neu-
ropsychological dimensions, with illness duration as the
covariate, were carried out and the same results were
obtained. In addition, separate equation regressions were
computed for insight dimensions at follow-up (depend-
ent variable) with insight dimensions and each one of the
five cognitive 'factor scores' at baseline (independent var-
iables). Our results revealed that baseline cognitive
dimensions did not predict change in insight dimensions
at follow-up. Lastly, a similar profile of results of a lack of
significant associations (i.e., between 'cognitive and
insight' measures and dimensions) was found in the
schizophrenia subset sample (n = 37). SPSS Regression
output in the total sample is provided by the supplemen-
tary material to this article (see Additional file 1)
Discussion
Overall, our results support findings that insight dimen-
sions and neuropsychological performance in patients
suffering from psychoses are non-associated domains.
Both cross-sectional and longitudinal analyses did not
achieve the level for statistical association after the ade-
quate statistical correction to avoid a Type I error. Moreo-
ver, a similar profile of 'lack of significant associations'
was found in the subset of patients with schizophrenia.
The discrepancy between our results and those of some of
the published studies might partly originate from several
sources, such as the selection of different target samples,
the use of unstandardized or non-specific scales for the
assessment of insight, statistical shortcomings (i.e., lack of
statistical correction to avoid Type I error), or unreliability
in neuropsychological assessment. Heterogeneity across
samples of previous studies was very common, since sev-
eral studies comprised mixed samples [10,18,21,40,65]
and others showed great differences in illness phase. As
examples of the latter, samples of previous studies range
from stable out-patients [7,8,38,39,41,66] to patients
assessed after remission of acute episodes [9,48], relatively
recent-onset patients [17,34] and first-episode psychotic
patients [15,16,30,35] to rather chronic populations
[22,31,37,47] or acute patients [26], and samples with
non-selected patients to samples comprising 'high insight'
patients or patients included in psychotherapeutic pro-
grams [19,45,46,67]. Some authors have suggested that
cognitive deficits do not relate to insight in the earlier
stages of the psychotic illness, but do in samples with
longer mean duration of illness [38,47]. In regards to
insight assessment, many studies have used unstandard-
ized instruments, such as Item 12 on the Positive and Neg-
ative Symptom Scale (PANSS) [20,39,43,48,67] or insight
items from general 'psychopathological inventories' (i.e.,
PSE [10,17] or AMDP [9,37]). These instruments have
demonstrated limitations when attempting to capture the
multidimensional aspects underlying insight.
Another source of inconsistency between studies emerged
from statistical grounds. Most studies have analyzed their
results using correlation or regression methods. However,
an exception to this was the use of adequate statistical cor-
rection, such as the Bonferroni inequality [9,37] or one-
tailed p [66], to avoid bias related to the performance of a
high number of statistical procedures. For instance, after
applying the Bonferroni correction to studies that
reported significant correlations between insight and cog-
nitive measures [18,20-26,31,32,42,46,67], few associa-
tions between insight or compliance and IQ remained at
a statistically significant level [43]. In addition, only two
studies by Young et al. [18,20] continued to show signifi-
cant correlations between lack of insight and executive
dysfunction. Caution is needed in the interpretation of
our results supporting our original hypothesis, since neg-
ative results arose from the application of the Bonfferoni
inequality correction to correlation coefficients. However,
Table 4: Pearson correlation coefficients between insight and cognitive dimensions at baseline(r0) and at follow-up assessments (r1)a.
INSIGHT DIMENSIONS
General awareness dimension r0/r1 Attitudes to treatment dimension r0/r1
General cognitive factor -.02/.01 -.01/.01
Perseverative factor .07/-.03 .05/-.07
Non-perseverative errors factor -.27*/-.15 .10/-.10
Inefficient sorting factor .01/-.15 .09/.10
Attentional-executive factor .15/.07 .06/.02
p ≤ 0.05 **p ≤ 0.01
a Critical p ≤ .05 value after Bonferroni correction for a 5 × 2 matrix was r = .36 p ≤ .005 (in bold). 95% confidence interval for significant associations 
(n = 56) ranged from r = .10 to r = .56.BMC Psychiatry 2006, 6:26 http://www.biomedcentral.com/1471-244X/6/26
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not only our results, but also the results of most studies
that have rendered a similar profile of a lack of significa-
tion associations between insight and cognitive perform-
ance were analyzed with the Bonfferoni inequality
correction.
There was some unreliability associated with neuropsy-
chological assessment in studies that have focused on
insight, such as limitations in the selection of neuropsy-
chological tests and conceptual inconsistency. For
instance, certain studies have exclusively used one test
that is hypothetically related to these areas, such as the
WCST [21,37,38,44] or tests only related to executive
function [19,47,48,67] and then concluded that lack of
insight was or was not associated with executive or frontal
dysfunction. However, this selective approach to neu-
ropsychological assessment cannot distinguish whether
lack of insight is or is not associated with a global cogni-
tive dysfunction [68]. Moreover, general tests for intelli-
gence assessment [9,17,69], the use of only a single test
[25,39] or the qualitative assessment of cognitive func-
tioning through 'clinical vignettes' [32] are not appropri-
ate neuropsychological instruments to use to reach firm
conclusions regarding insight and cognitive functioning.
Conclusion
Our present data is consistent with previous results from
our group. We have previously hypothetized that insight
dimensions are semi-independent domains of psychopa-
thology regarding schizophrenic symptomatology.
Insight dimensions have a 'primary' origin from a Bleule-
rian perspective [9,50,70]. In this regard, lack of insight
should be considered a characteristic manifestation of
patients suffering from psychosis. Our hypothesis is also
supported by the lack of significant correlations between
lack of insight and cognitive performance, which are
found in other 'characteristic symptoms' of psychosis such
as delusions or hallucinations. This does not mean that
there is no biological substrate for psychotic symptoms,
but that the relationships between clinical and cognitive
domains seem to be too complex to be reduced to a single
direct association.
There are a number of limitations in the present study that
might reduce the strength of our results and should there-
fore be acknowledged. First, the use of factor scores to
summarize insight measures might have resulted in differ-
ent insight constructs compared to other studies. How-
ever, an inspection of the raw data led us to disregard any
significant associations that were found between cognitive
and insight measures. Second, missing values on the
SUMD scale were replaced by its mean value and included
in factor analysis conjointly with other insight measures.
These other insight measures included values resulting
from the ITAQ and AMDP instruments, which were avail-
able for all patients. This modification in the SUMD scale
should be taken into account when comparing our results
with other studies, since our methods used to extract fac-
tor scores might generate different insight constructs.
Third, in spite of the fact that our sample was one of the
largest in the literature, the inability to detect significant
associations might represent a Type II error (i.e., lack of
statistical power due to small sample size). In fact, for the
highest correlation in Table 3 (correlation of .30 between
AMDP refusal of treatment and WCST number of catego-
ries at follow-up), a sample size of 85 would have been
needed to establish that correlation alone as statistically
significant (power ≥ 0.80). Similarly, a sample size of 105
would have been needed to determine the highest correla-
tion in Table 4 (correlation of -.27 between 'non-persever-
ative' factor and 'general awareness' dimension) as
statistically significant. And fourth, cognitive assessment
of patients during acute episodes might denote greater cri-
ses rather than poorer performance. However, the first
point of assessment occurred once our patients were stabi-
lized from the episode of psychosis, which was more than
3 weeks after the time of admission.
A pending question that can be derived from our results is:
What are the neurobiological underpinnings of lack of
insight? The absence of statistically significant associa-
tions between lack of insight and cognitive performance
does not imply that insight dimensions do not hold
pathophysiological correlates. On the contrary, it has
been suggested that complex symptoms, such as lack of
insight, are greatly influenced and distorted by the indi-
vidual's socio-cultural background and language, as well
as by the process of symptom formation itself. This occurs
because less elaborate symptoms are more related to the
biological substrate. In other words, the more complex
the symptom, the farther the original signal is from the
brain [71]. Following this line of reasoning, the search for
'clinical mediators' or simpler domains of psychopathol-
ogy, such as hope [72], affect [73] and metacognition
[74], might be relevant for understanding the neurobio-
logical correlates of insight dimensions. Future studies
that investigate the neurobiological dysfunction underly-
ing psychosis should undertake the research starting with
less-structured behaviors or from 'basic' dimensions from
lower hierarchical levels [75].
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